Synonyms: Rescula® (proposed trade name) | UF 021 | UF-021
unoprostone isopropyl is an approved drug (FDA (2000))
Compound class:
Synthetic organic
Comment: Note that the INN for this compound is for the carboxylic acid, whereas the compound used clinically is the isopropyl ester.
Unoprostone was originally developed as an intraocular pressure-reducing agent for use in glaucoma, however use for this indication has been discontinued. The focus is now on unoprostone's ability to treat retinal disease [3,5]. ![]() View more information in the IUPHAR Pharmacology Education Project: unoprostone isopropyl |
|
No information available. |
Summary of Clinical Use ![]() |
Both the EMA and FDA have granted unoprostone isopropyl orphan drug status for the treatment of the rare condition retinitis pigmentosa (RP) [7]. A Phase 2I clinical trial assessing unoprostone isopropyl as a treatment for RP is ongoing. A Phase 2 study in patients with dry age-related macular degeneration has been completed. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Unoprostone isopropyl is a topically applied prostaglandin analogue, with a docosanoid-like structure. Docosanoids are signaling molecules with neuroprotective and anti-inflammatory actions [1]. The reported affinity of unoprostone for prostaglandin receptors is very low [4], suggesting an alternative mechanism of action. The beneficial effects of unoprostone in RP appear to be mediated by activation of Ca2+-activated K+ (BK) channels [6], with an EC50 for activation of BK channels by unoprostone of approximately 0.6 nM in human cortical cells [2]. |